SHANGHAI, NANJING, CHINA, and SAN JOSE,
Calif., July 1, 2024 /PRNewswire/ -- IASO
biotechnology ("IASO Bio"), a biopharmaceutical company engaged in
discovering, developing, manufacturing and marketing innovative
cell therapies and antibody products, presented the
clinical data and single-cell analysis of the fully human anti-BCMA
CAR T cell therapy (Equecabtagene Autoleucel, Eque-cel) for the
treatment of central nervous system autoimmunity in an oral
presentation at the 2024 European Academy of Neurology (EAN) Annual
Meeting.
Presentation Title: Single-cell analysis of
anti-BCMA CAR T cell therapy in patients with central nervous
system autoimmunity
Presentation Type: Oral report
Session Date and Time: 1 July 2024, 8:30 - 9:45
(EEST)
Location: Helsinki, Finland
Publication Number: A-24-12777
Presenter: Professor Chuan Qin, Tongji Hospital,
Tongji Medical College, Huazhong University of Science and
Technology
This report is based on an investigator-initiated study to
evaluate the safety and efficacy of Eque-cel for the treatment of
relapsed/refractory antibody-mediated idiopathic inflammatory
disorders of the nervous system (NCT04561557). It was
conducted by Professor Wei Wang's
team at Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology.
The study enrolled 12 subjects with aquaporin-4 (AQP4)
antibody-positive relapsed/refractory neuromyelitis optica spectrum
disorder (NMOSD), all of whom had been treated with at least one
immunosuppressant for over a year but had poor symptom control. The
study results preliminarily demonstrated the good tolerability and
safety, durable pathogenic antibody clearance, and potential
clinical efficacy of Eque-cel in NMOSD. And CAR-T cells with
chemotactic properties can cross the blood-brain barrier and enter
the central nervous system to directly kill abnormal plasma cells
in the central nervous system. The action facilitates the
restoration of central immunity as it reduces the secretion of
autoantibodies within sheaths and the abnormal activation of immune
cells. As a result, the immune disorder in the central nervous
system of the NMOSD patients can be rectified and its immune system
can be reset.
As one of the pioneering research teams that first use BCMA
CAR-T therapy for the treatment of immune diseases in the world,
Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology and IASO Bio have achieved breakthrough
research results that validate the clinical value of innovative
cell therapy for relapsed and refractory immune diseases, making
its application prospects increasingly recognized and valued
internationally. Currently, BCMA CAR-T therapy has been rated as
one of the most promising treatment strategies by the
International Neuromyelitis Optica Study Group (NEMOS) and
incorporated into the latest revised treatment recommendations (J
Neurol 2024). In addition, Professor Maximilian F. Konig from department of
immunology, Johns Hopkins University,
stated in Year in review, Immunotherapies in 2023: The rise of
precision cellular therapies, published in Nat Rev
Rheumatol, that the application of CAR-T therapy has brought
groundbreaking advancements in innovative cellular therapies for
immune diseases.
Professor Wei Wang from Tongji
Hospital, Tongji Medical College, Huazhong University of Science
and Technology, the principal investigator of this study,
stated: "This study was the world's first clinical trial of CAR-T
therapy in the field of AQP4-mediated relapsed/refractory NMOSD. It
not only demonstrated the encouraging efficacy and controllable
safety of Eque-cel in NMOSD but also elucidated the cellular
dynamics and immunological characteristics of CAR-T therapy for
central nervous system autoimmune diseases. This provides a new
therapeutic approach for antibody-mediated autoimmune diseases and
also provides scientific insights into refining CAR-T cell
therapies for autoimmune diseases. In addition to NMOSD, Eque-cel
has shown an excellent clinical efficacy in the treatment of other
antibody-mediated autoimmune diseases, including myasthenia gravis
and immune-mediated necrotizing myopathy, even with early signs of
reversing the disease. We have published several related research
papers in leading international academic journals. There is a large
patient population with autoimmune diseases, which are prone to
relapses, difficult to cure, and require long-term or even lifelong
medication, with a huge unmet clinical demand. We will continue to
explore the application of Eque-cel in more refractory autoimmune
diseases with IASO Bio team, aiming to transform the treatment
landscape of autoimmune diseases."
About IASO Bio
IASO Bio is a biopharmaceutical company engaged in the discovery
and development of novel cell therapies and biologics for oncology
and autoimmune diseases. IASO Bio possesses comprehensive
capabilities spanning the entire drug development process, from
early discovery to clinical development, regulatory approval, and
commercial production.
The pipeline in the company includes a diversified portfolio of
over 10 novel products, including Equecabtagene Autoleucel (a fully
human BCMA CAR-T injection). Equecabtagene Autoleucel received New
Drug Application (NDA) approval from China's National Medical Products
Administration (NMPA) and U.S. FDA IND approval for the treatment
of RRMM.
Leveraging its strong management team, innovative product
pipeline, GMP production, as well as integrated manufactural and
clinical capabilities, IASO aims to deliver transformative,
curable, and affordable therapies that fulfil unmet medical needs
to patients in China as well as
around the world. For more information, please visit
http://www.iasobio.com or
www.linkedin.com/company/iasobiotherapeutics.
View original
content:https://www.prnewswire.com/news-releases/iaso-bio-presented-clinical-data-and-single-cell-analysis-of-equecabtagene-autoleucel-for-the-treatment-of-central-nervous-system-autoimmunity-in-oral-presentation-at-ean-congress-2024-302186742.html
SOURCE IASO Bio